Hans Joachim Schmoll

Summary

Publications

  1. ncbi request reprint ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making
    H J Schmoll
    Department of Oncology Haematology, Martin Luther University Halle, Germany
    Ann Oncol 23:2479-516. 2012
  2. doi request reprint Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III)
    Hans Joachim Schmoll
    Department of Internal Medicine IV, Hematology and Oncology, University Clinic Halle Saale, Martin Luther University Halle Wittenberg, Ernst Grube Str 40, 06120 Halle, Germany
    J Clin Oncol 30:3588-95. 2012
  3. pmc Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature
    Alexander Stein
    University Cancer Center Hamburg, Germany
    BMC Cancer 12:356. 2012
  4. ncbi request reprint Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer
    Thomas Mueller
    Department of Hematology Oncology, Martin Luther University of Halle Wittenberg, 06120 Halle, Germany
    Cancer Res 63:513-21. 2003
  5. ncbi request reprint Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard?
    Hans Joachim Schmoll
    Department of Haematology Oncology, Internal Medicine Clinic, Martin Luther University, 06120 Halle, Germany
    Lancet 370:105-7. 2007
  6. ncbi request reprint Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance
    Thomas Mueller
    Department of Medicine IV, Hematology Oncology, Martin Luther University Halle Wittenberg, Center of Applied Medical and Human Biological Research, Heinrich Damerow Strasse 1, Halle DE 06120, Germany
    Tumour Biol 27:71-83. 2006
  7. doi request reprint Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer
    Gregor Seliger
    Department of Gynecology, Martin Luther University Halle Wittenberg, Halle, Germany
    Int J Gynecol Cancer 19:1446-53. 2009
  8. ncbi request reprint Resistance mechanisms following cisplatin and oxaliplatin treatment of the human teratocarcinoma cell line 2102EP
    Anja Rennicke
    Department of Medical Oncology and Hematology, Martin Luther University Halle Saale, Ernst Grube Str 40, D 06120 Halle Saale, Germany
    Anticancer Res 25:1147-55. 2005
  9. ncbi request reprint Histological evidence for the existence of germ cell tumor cells showing embryonal carcinoma morphology but lacking OCT4 expression and cisplatin sensitivity
    Thomas Mueller
    Department of Internal Medicine IV, Oncology Hematology, Martin Luther University Halle Wittenberg, 06120 Halle, Germany
    Histochem Cell Biol 134:197-204. 2010
  10. ncbi request reprint Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment
    Karin Jordan
    Department of Internal Medicine IV, Haematology Oncology, Martin Luther University Halle Wittenberg, Ernst Grube Str 40, 06120 Halle Saale, Germany
    Eur J Cancer 41:199-205. 2005

Detail Information

Publications26

  1. ncbi request reprint ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making
    H J Schmoll
    Department of Oncology Haematology, Martin Luther University Halle, Germany
    Ann Oncol 23:2479-516. 2012
    ..This ESMO guideline is recommended to be used as the basis for treatment and management decisions...
  2. doi request reprint Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III)
    Hans Joachim Schmoll
    Department of Internal Medicine IV, Hematology and Oncology, University Clinic Halle Saale, Martin Luther University Halle Wittenberg, Ernst Grube Str 40, 06120 Halle, Germany
    J Clin Oncol 30:3588-95. 2012
    ....
  3. pmc Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature
    Alexander Stein
    University Cancer Center Hamburg, Germany
    BMC Cancer 12:356. 2012
    ..Besides multidisciplinary management further treatment intensification is warranted to improve the still limited prognosis...
  4. ncbi request reprint Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer
    Thomas Mueller
    Department of Hematology Oncology, Martin Luther University of Halle Wittenberg, 06120 Halle, Germany
    Cancer Res 63:513-21. 2003
    ..However, additional defining and eventually targeting the exact molecular mechanism blocking caspase-9 activation might lead to more selective therapeutic approaches to overcome cisplatin resistance in germ cell cancer...
  5. ncbi request reprint Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard?
    Hans Joachim Schmoll
    Department of Haematology Oncology, Internal Medicine Clinic, Martin Luther University, 06120 Halle, Germany
    Lancet 370:105-7. 2007
  6. ncbi request reprint Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance
    Thomas Mueller
    Department of Medicine IV, Hematology Oncology, Martin Luther University Halle Wittenberg, Center of Applied Medical and Human Biological Research, Heinrich Damerow Strasse 1, Halle DE 06120, Germany
    Tumour Biol 27:71-83. 2006
    ..In contrast, the presence of the Oct-3/4-positive, highly sensitive EC cells as the tumor stem cell component in most TGCTs could explain the general high chemosensitivity and curability of these tumors...
  7. doi request reprint Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer
    Gregor Seliger
    Department of Gynecology, Martin Luther University Halle Wittenberg, Halle, Germany
    Int J Gynecol Cancer 19:1446-53. 2009
    ..This phase 2 trial was designed to evaluate the efficacy and toxicity of a combination of docetaxel, gemcitabine, and oxaliplatin for platinum- and paclitaxel-pretreated epithelial ovarian cancer...
  8. ncbi request reprint Resistance mechanisms following cisplatin and oxaliplatin treatment of the human teratocarcinoma cell line 2102EP
    Anja Rennicke
    Department of Medical Oncology and Hematology, Martin Luther University Halle Saale, Ernst Grube Str 40, D 06120 Halle Saale, Germany
    Anticancer Res 25:1147-55. 2005
    ..Oxaliplatin and cisplatin are widely used in cancer chemotherapy, however, their clinical efficiency is often limited by the development of resistance...
  9. ncbi request reprint Histological evidence for the existence of germ cell tumor cells showing embryonal carcinoma morphology but lacking OCT4 expression and cisplatin sensitivity
    Thomas Mueller
    Department of Internal Medicine IV, Oncology Hematology, Martin Luther University Halle Wittenberg, 06120 Halle, Germany
    Histochem Cell Biol 134:197-204. 2010
    ..This challenges the use of the term EC cell. The data also support our hypothesis that malignant growth of resistant NSGCT may be driven by this cell type...
  10. ncbi request reprint Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment
    Karin Jordan
    Department of Internal Medicine IV, Haematology Oncology, Martin Luther University Halle Wittenberg, Ernst Grube Str 40, 06120 Halle Saale, Germany
    Eur J Cancer 41:199-205. 2005
    ..Due to these new developments, revised antiemetic guidelines have been set. Here, the most recent developments in antiemetic therapy, including these guidelines, are reviewed...
  11. doi request reprint Reduction of chemotherapy-induced anorexia, nausea, and emesis through a structured nursing intervention: a cluster-randomized multicenter trial
    Patrick Jahn
    Institute for Health and Nursing Science, Medical Faculty, Martin Luther University Halle Wittenberg, Magdeburger Strasse 8, 06097, Halle, Germany
    Support Care Cancer 17:1543-52. 2009
    ..The purpose of this present study was to evaluate Self-care Improvement through Oncology Nursing (SCION) program to reduce distressing anorexia, nausea, and emesis (ANE) in cancer patients undergoing chemotherapy...
  12. doi request reprint Growth inhibition of colorectal carcinoma by lentiviral TRAIL-transgenic human mesenchymal stem cells requires their substantial intratumoral presence
    Jana Luetzkendorf
    Department of Internal Medicine IV, Oncology Hematology, Martin Luther University Halle Wittenberg, Halle, Germany
    J Cell Mol Med 14:2292-304. 2010
    ....
  13. doi request reprint Pulmonary embolism in oncologic patients: frequency and embolus burden of symptomatic and unsuspected events
    Andreas Gunter Bach
    Department of Radiology, Martin Luther University Halle Wittenberg, Halle, Germany
    Acta Radiol 55:45-53. 2014
    ..Pulmonary embolism (PE) is a common cause of morbidity and mortality in oncologic patients. Furthermore, PE is an unsuspected finding in many cases...
  14. ncbi request reprint Dihydropyrimidine dehydrogenase inhibition as a strategy for the oral administration of 5-fluorouracil: utility in the treatment of advanced colorectal cancer
    Hans Joachim Schmoll
    Department of Internal Medicine, Martin Luther University Halle, Halle Saale, Germany
    Anticancer Drugs 14:695-702. 2003
    ..Thus the DPD-inhibiting oral fluoropyrimidines have failed to fulfill their early promise: clinical data indicate that none of these compounds is likely to improve outcomes for patients with metastatic colorectal cancer...
  15. ncbi request reprint Detection of an occult B-cell lymphoma in the donor's bone marrow prior to HLA-matched sibling transplantation
    William H Krüger
    Department of Internal Medicine, Division of Hematology Oncology, Martin Luther University Halle Wittenberg, 06120 Halle Saale, Germany
    J Hematother Stem Cell Res 11:169-70. 2002
  16. ncbi request reprint Biomolecules linked to transition metal complexes--new chances for chemotherapy
    Reinhard Paschke
    Biocenter, Martin Luther University Halle Wittenberg, 06099 Halle, Germany
    Curr Med Chem 10:2033-44. 2003
    ..The main issues are: selection of the drug and the carrier, ways of linking the pharmacological active compound to the biomolecule, the optimal way of linking the drug to the spacer, and cytotoxicity, apoptosis, and drug resistance...
  17. ncbi request reprint Update on capecitabine in colorectal cancer
    Hans Joachim Schmoll
    Department of Internal Medicine IV, Hematology and Oncology, Martin Luther University Halle Wittenberg, 06120 Halle, Germany
    Oncologist 11:1003-9. 2006
    ..While capecitabine is generally well tolerated, its potential toxicities need careful management and may require individual dose adaption...
  18. ncbi request reprint Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats
    Marina Fittkau
    Institute of Clinical Chemistry, Martin Luther University Halle Wittenberg, Magdeburger Strasse 24, 06097 Halle Saale, Germany
    J Cancer Res Clin Oncol 130:388-94. 2004
    ..To evaluate the ability of D-saccharic acid 1.4-lactone (SAL), a beta-glucuronidase inhibitor, to prevent irinotecan hydrochloride (CPT-11) from inducing mucosal damage as a cause of diarrhea in rats...
  19. ncbi request reprint Successful treatment of mediastinal lymphomatoid granulomatosis with rituximab monotherapy
    Karin Jordan
    Internal Medicine IV, Hematology Oncology, Martin Luther University Halle Wittenberg, Halle Saale, Germany
    Eur J Haematol 74:263-6. 2005
    ..Rituximab was continued for another 6 months with subsequent consolidation radiotherapy. This is the first report of an enduring complete remission (20 months) of a non-CNS lymphomatoid granulomatosis treated with rituximab...
  20. ncbi request reprint Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations
    Karin Jordan
    Department of Internal Medicine IV, Oncology Hematology, Martin Luther University Halle Wittenberg, Ernst Grube Str 40, 06120 Halle Saale, Germany
    Oncologist 12:1143-50. 2007
    ..This review focuses, in particular, on the conformity and differences of these three guidelines. Furthermore, open questions and trends in the field of antiemesis are discussed as well...
  21. doi request reprint Adjuvant therapy for early colon cancer: current status
    Alexander Stein
    University Cancer Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Drugs 71:2257-75. 2011
    ..The impact of these current developments on daily clinical practice is discussed in this review...
  22. doi request reprint Metastases to the breast from non-mammary malignancies: primary tumors, prevalence, clinical signs, and radiological features
    Alexey Surov
    Department of Radiology, Martin Luther University Halle Wittenberg, Germany
    Acad Radiol 18:565-74. 2011
    ..Breast metastases (BM) from nonmammary malignancies are very rare. The aims of this study were to estimate retrospectively the prevalence of BM from nonmammary malignancies and to describe their radiologic appearance...
  23. ncbi request reprint Presence of mesenchymal stem cells in human bone marrow after exposure to chemotherapy: evidence of resistance to apoptosis induction
    Lutz P Mueller
    Department of Medicine IV, Hematology Oncology, Centre for Applied Medical and Human Biological Research, Martin Luther University Halle Wittenberg, Halle, Germany
    Stem Cells 24:2753-65. 2006
    ..Our data suggest that an elevated apoptotic threshold contributes not only to the persistence of hMSCs in the BM after chemotherapy but also to their lifelong presence in the adult BM...
  24. ncbi request reprint Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer
    Jochen H Lorch
    Department of Hematology and Oncology, Martin Luther University Halle, Halle, Germany
    Cancer Res 67:727-34. 2007
    ..Collectively, our results suggest that proteasome inhibition using bortezomib affects cell adhesion and cell migration profoundly and provides a rationale for its clinical use in conjunction with an EGFR inhibitor...
  25. doi request reprint German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors
    Henning Dralle
    Department of General, Visceral and Vascular Surgery, Martin Luther University Halle Wittenberg, Ernst Grube Straße 40, 06097, Halle, Saale, Germany
    Langenbecks Arch Surg 398:347-75. 2013
    ..These developments called for an update of the previous practice guideline to detail the surgical treatment options that are available for the various disease entities and tumor stages...
  26. doi request reprint Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy
    Karin Jordan
    Department of Internal Medicine IV, Oncology Hematology, Martin Luther University Halle Wittenberg, Ernst Grube Str 40, 06120 Halle, Saale, Germany
    Eur J Cancer 45:1184-7. 2009
    ..In multiple-day chemotherapy (MDC), the combination of a 5-HT(3)-antagonist plus dexamethasone is still a standard of care. The role of a NK-1-antagonist remains to be defined...